CME Presentations

Chronic Idiopathic Urticaria



  • Allen P. Kaplan, MD

    Allen P. Kaplan, MD

    Allen P. Kaplan, MD

    Allen Kaplan, MD, is professor of medicine at The Medical University of South Carolina in Charleston. Dr Kaplan was head of the Allergic Diseases Section of the NIAID for 6 years, head of the Division of Allergy, Rheumatology, and Clinical Immunology, and chairman of the Department of Medicine at Stony Brook University for 19 total years. Author of over 365 publications, his interests are mechanisms for production of bradykinin and its role in human disease, and pathogenesis and treatment of urticaria and angioedema. Dr Kaplan has been president of AAAAI, the Clinical Immunology Society, and The World Allergy Organization. He edited The Journal of The World Allergy Organization for five years and has edited or co-edited many other notable journals and textbooks.
  • Jonathan A. Bernstein, MD

    Jonathan A. Bernstein, MD

    Jonathan A. Bernstein, MD

    Jonathan A. Bernstein, MD, is professor of clinical medicine in the Department of Internal Medicine, Division of Immunology/Allergy Section at the University of Cincinnati Medical Center and partner of the Bernstein Allergy Group and Clinical Research Center in Cincinnati, Ohio. His research, which has resulted in over 310 peer reviewed articles, involves effects of environmental interventions in homes of asthmatic children, and therapies for treatment of angioedema/chronic urticaria. Dr Bernstein is vice-chairman of the AAAAI Foundation, president of Interasma, and chairman of AFI. He was the recipient of the 2019 AAAAI Distinguished Clinician and WAO Outstanding Clinician awards. Dr Bernstein has been ranked by US News and World Report as being in the top 1% of doctors in his specialty.
  • Sanaz Eftekhari

    Sanaz Eftekhari

    Sanaz Eftekhari

    Sanaz Eftekhar, vice president of Corporate Affairs and Research at AAFA, leads tactical and strategic conversations with business partners and stakeholders across multiple industries. She has been instrumental in working with AAFA’s partners to present patient perspectives on the needs for atopic dermatitis treatments to the US Food and Drug Administration. In a greater effort to connect patients with vital clinical trials, Sanaz has been a key player in the development of AAFA’s upcoming clinical trial database. She has led AAFA’s involvement in the CIU & You campaign since its launch in 2015, co-authored several key AAFA research reports, and serves as secretary on the Board of Directors for the Global Allergy & Airways Patient Platform (GAAPP).

CME Information

Chronic Spontaneous (Idiopathic) Urticaria (CSU or CIU): Engaging Patients to Enable Earlier Diagnosis and Timely Therapeutic Decisions

Global LogoPQH Logo


After completing this activity, the participant should be better able to:

  • Perform thorough patient history and evaluation to accurately and quickly differentiate CSU from other forms of urticaria and other dermatologic conditions
  • Explain how to apply the most recent guidelines for the definition, classification, diagnosis and management of urticaria to the symptomatic management of CSU, promptly identifying patients who are refractory to H1-antihistamine therapy and who would benefit from anti-IgE therapy
  • Describe how to employ a shared decision-making approach to the management of patients with CSU, assessing disease burden at every visit to guide prompt change and adjustment in therapy or referral to a specialist
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.


This activity is supported by an educational grant from Genentech.


There is no fee for this educational activity.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity was released on May 7, 2020 and is valid for 12 months. Requests for credit must be made no later than May 7, 2021.


The educational design of this activity addresses the needs of primary care physicians, nurse practitioners, physician assistants, allergists, dermatologists and other healthcare professionals involved in the management of patients with CSU (CIU).


Despite updates to guidelines calling for a rapid treatment titration protocol with evidence-based management options, patients who are affected by chronic spontaneous urticaria (CSU), also named chronic idiopathic urticaria (CIU), and their caretakers continue to suffer from great disease burden and impaired functional ability due to diagnostics delay, and underdosing of medications. Many patients cycle through different treatments, including self-prescribed, over-the-counter options, seeing different physicians, without achieving long-term symptom relief.

In this activity, the faculty panel will discuss the challenges inherent in treating this skin condition characterized with unexplained breakthroughs, and that greatly impairs the quality of life of those who are affected. This lively, interactive discussion between two allergy specialists will thoroughly discuss the signs of CSU, the underlying pathophysiology of the condition, and latest US and international recommendation for its management. The faculty will also discuss key learnings and questions collected directly from patients with CSU during a prior webcast designed to help people with CSU in their interaction with their doctor and in managing their condition.


This activity should take approximately 1 hour to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Allen P. Kaplan, MD
Professor of Medicine
Medical University of South Carolina
Advisory Board: Allakos, Biocryst, CSL Behring, Genentech, Sanofi-Aventis
Jonathan A. Bernstein, MD
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section
Bernstein Allergy Group and Bernstein Clinical Research Center
Consultant/Independent Contractor: Allakos, AstraZeneca, Biocyrst, CSL Behring, Kalvista, Novartis/Genentech, Pharming, Sanofi Regeneron, Shire/Takeda
Grant Research Support: Allakos, AstraZeneca, Biocyrst, CSL Behring, ISIS, Kalvista, Novartis/Genentech, Pharming, Sanofi Regeneron, Shire/Takeda
Honoraria: Allakos, AstraZeneca, CSL Behring, Novartis/Genentech, Pharming, Sanofi Regeneron, Shire/Takeda
Speaker’s Bureau: Allakos, AstraZeneca, CSL Behring, Novartis/Genentech, Pharming, Sanofi Regeneron, Shire/Takeda
Advisory Board: Allakos, AstraZeneca, Biocyrst, CSL Behring, ISIS, Kalvista, Novartis/Genentech, Pharming, Sanofi Regeneron, Shire/Takeda
Sanaz Eftekhari
Vice President, Corporate Affairs and Research
Asthma and Allergy Foundation of America (AAFA
Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Carole Drexel Nothing to disclose
Alissa Yost Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:
For any technical issues or issues with your CME Certificate, please contact ImmunologyLive at 877-394-1306 or at Support@ImmulnologyLive.